Nuclear Medicine or Radiopharmaceuticals Market Targets US$ 11.0 Billion Milestone by 2032
Nuclear Medicine or Radiopharmaceuticals Market Size Was Valued at USD 6.13 Billion in 2022, and is Projected to Reach USD 11.0 Billion by 2030, Growing at a CAGR of 7.6% From 2023-2030.
Nuclear medicine is a specialized field within the medical domain that utilizes small amounts of radioactive materials, known as radiopharmaceuticals, to diagnose and treat diseases. Radiopharmaceuticals are compounds consisting of a radioactive substance (radionuclide) combined with a pharmaceutical agent. These substances emit gamma rays that can be detected by specialized cameras or scanners, allowing physicians to visualize and assess the functioning of organs or tissues within the body.
In this report, the nuclear medicine market has been segmented based on type, application, procedure volume and region. Based on type, the nuclear medicine market is categorized into diagnostic and therapeutic nuclear medicine. The therapeutic nuclear medicine segment is further segmented into alpha emitters, beta emitters, and brachytherapy isotopes. The diagnostic nuclear medicine segment is segmented into SPECT and PET.
Key Prominent Players In The Nuclear Medicine or Radiopharmaceuticals Market:
Actinium Pharmaceuticals Inc. (U.S.),Alliance Medical (U.K.),Avid Bioservices Inc(U.S.),Bayer Healthcare Pharmaceuticals (Germany),Bracco Diagnostics Inc. (Italy),Cardinal Health Inc. (U.S.),Ge Healthcare (U.S.),Ion Beam Applications S.A (Belgium),Jubilant Pharma (India),Lantheus Medical Imaging Inc. (U.S.),Medi-Radiopharma Ltd (Hungary),Nordion Inc. (Canada),Novartis/Advanced Accelerator Applications (France),Positron Corporation (U.S.),Radiopharm Theranostics Ltd. (U.S.),Curium (France),Eli Lilly And Company (U.S.),Fujifilm Toyama Chemical Co., Ltd. (Japan),Nihon Medi-Physics. Co. Ltd. (Japan),Samyoung Unitech (South Korea),Duchembio, Inc. (South Korea) and Other Major Players.
Know More About The Global Trends Impacting The Future, Download A PDF Sample@:
https://introspectivemarke...
Nuclear Medicine or Radiopharmaceuticals Market Size Was Valued at USD 6.13 Billion in 2022, and is Projected to Reach USD 11.0 Billion by 2030, Growing at a CAGR of 7.6% From 2023-2030.
Nuclear medicine is a specialized field within the medical domain that utilizes small amounts of radioactive materials, known as radiopharmaceuticals, to diagnose and treat diseases. Radiopharmaceuticals are compounds consisting of a radioactive substance (radionuclide) combined with a pharmaceutical agent. These substances emit gamma rays that can be detected by specialized cameras or scanners, allowing physicians to visualize and assess the functioning of organs or tissues within the body.
In this report, the nuclear medicine market has been segmented based on type, application, procedure volume and region. Based on type, the nuclear medicine market is categorized into diagnostic and therapeutic nuclear medicine. The therapeutic nuclear medicine segment is further segmented into alpha emitters, beta emitters, and brachytherapy isotopes. The diagnostic nuclear medicine segment is segmented into SPECT and PET.
Key Prominent Players In The Nuclear Medicine or Radiopharmaceuticals Market:
Actinium Pharmaceuticals Inc. (U.S.),Alliance Medical (U.K.),Avid Bioservices Inc(U.S.),Bayer Healthcare Pharmaceuticals (Germany),Bracco Diagnostics Inc. (Italy),Cardinal Health Inc. (U.S.),Ge Healthcare (U.S.),Ion Beam Applications S.A (Belgium),Jubilant Pharma (India),Lantheus Medical Imaging Inc. (U.S.),Medi-Radiopharma Ltd (Hungary),Nordion Inc. (Canada),Novartis/Advanced Accelerator Applications (France),Positron Corporation (U.S.),Radiopharm Theranostics Ltd. (U.S.),Curium (France),Eli Lilly And Company (U.S.),Fujifilm Toyama Chemical Co., Ltd. (Japan),Nihon Medi-Physics. Co. Ltd. (Japan),Samyoung Unitech (South Korea),Duchembio, Inc. (South Korea) and Other Major Players.
Know More About The Global Trends Impacting The Future, Download A PDF Sample@:
https://introspectivemarke...
6 months ago
